Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study

Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study

<p><strong>Background</strong> Ten-valent pneumococcal conjugate vaccine (PCV10), delivered at 6, 10, and 14 weeks of age was introduced in Kenya in January, 2011, accompanied by a catch-up campaign in Kilifi County for children aged younger than 5 years. Coverage with at least two...

Bibliografiset tiedot
Päätekijät:	Hammitt, LL, Etyang, AO, Morpeth, SC, Ojal, J, Mutuku, A, Mturi, N, Moisi, JC, Adetifa, IM, Karani, A, Akech, DO, Otiende, M, Bwanaali, T, Wafula, J, Mataza, C, Mumbo, E, Tabu, C, Knoll, MD, Bauni, E, Marsh, K, Williams, TN, Kamau, T, Sharif, SK, Levine, OS, Scott, JAG
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	Elsevier 2019

Samankaltaisia teoksia

The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria
Tekijä: Adamu, AL, et al.
Julkaistu: (2023)

The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria
Tekijä: Aishatu L. Adamu, et al.
Julkaistu: (2023-05-01)

Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya
Tekijä: Ojal, J, et al.
Julkaistu: (2019)

Effect of 10-valent pneumococcal conjugate vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children: an interrupted time-series analysis
Tekijä: Silaba, M, et al.
Julkaistu: (2019)

Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies
Tekijä: Dr. Laura L Hammitt, MD, et al.
Julkaistu: (2014-07-01)

Coverage and timeliness of vaccination and the validity of routine estimates: Insights from a vaccine registry in Kenya
Tekijä: Adetifa, I, et al.
Julkaistu: (2018)

Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children
Tekijä: Ayieko, P, et al.
Julkaistu: (2013)

Cohort profile: The Kilifi Vaccine Monitoring Study
Tekijä: Adetifa, I, et al.
Julkaistu: (2016)

Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data
Tekijä: Ojal, J, et al.
Julkaistu: (2017)

Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial.
Tekijä: Laura L Hammitt, et al.
Julkaistu: (2014-01-01)

Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children.
Tekijä: Philip Ayieko, et al.
Julkaistu: (2013-01-01)

Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
Tekijä: Anna M.M. van Deursen, et al.
Julkaistu: (2012-11-01)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly.
Tekijä: Irina Kislaya, et al.
Julkaistu: (2019-01-01)

Effect of 10-valent pneumococcal conjugate vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children: an interrupted time-series analysis
Tekijä: Micah Silaba, MMed, et al.
Julkaistu: (2019-03-01)

Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya
Tekijä: John Ojal, PhD, et al.
Julkaistu: (2019-05-01)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
Tekijä: V. K. Tatochenko, et al.
Julkaistu: (2012-03-01)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
Tekijä: Kristiana Alexandrova Nikolova, et al.
Julkaistu: (2021-10-01)

Population immunity to pneumococcal serotypes in Kilifi, Kenya, before and 6 years after the introduction of PCV10 with a catch-up campaign: an observational study of cross-sectional serosurveys
Tekijä: Gallagher, KE, et al.
Julkaistu: (2023)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
Tekijä: James T. Peterson, et al.
Julkaistu: (2019-03-01)

Decrease in pneumococcal co-colonization following vaccination with the seven-valent pneumococcal conjugate vaccine.
Tekijä: Carina Valente, et al.
Julkaistu: (2012-01-01)

13-valent pneumococcal conjugate vaccine in Africa
Tekijä: Robert Cohen, et al.
Julkaistu: (2017-03-01)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
Tekijä: N. L. Chernaya, et al.
Julkaistu: (2012-02-01)

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine.
Tekijä: Sweta M Patel, et al.
Julkaistu: (2022-01-01)

PNEUMOCOCCAL INFECTION VACCINAL PREVENTION EFFICACY IN CHILDREN USING PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE
Tekijä: N. L. Chernaya, et al.
Julkaistu: (2013-01-01)

Mortality of Invasive Pneumococcal Disease following Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Greenland
Tekijä: Kristiana Alexandrova Nikolova, et al.
Julkaistu: (2024-02-01)

Pneumococcal meningitis: epidemiological profile pre‐ and post‐introduction of the pneumococcal 10‐valent conjugate vaccine
Tekijä: Tatiane E. Hirose, et al.
Julkaistu: (2015-03-01)

Pneumococcal meningitis: epidemiological profile pre- and post-introduction of the pneumococcal 10-valent conjugate vaccine
Tekijä: Tatiane E. Hirose, et al.
Julkaistu: (2015-03-01)

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine
Tekijä: Sweta M. Patel, et al.
Julkaistu: (2022-01-01)

Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia
Tekijä: Paul Turner, et al.
Julkaistu: (2015-11-01)

Population genetic structure of Streptococcus pneumoniae in Kilifi, Kenya, prior to the introduction of pneumococcal conjugate vaccine
Tekijä: Brueggemann, A, et al.
Julkaistu: (2013)

Population genetic structure of Streptococcus pneumoniae in Kilifi, Kenya, prior to the introduction of pneumococcal conjugate vaccine
Tekijä: Brueggemann, AB, et al.
Julkaistu: (2013)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
Tekijä: George Gourzoulidis, et al.
Julkaistu: (2023-09-01)

Impact of viral upper respiratory tract infection on the concentration of nasopharyngeal pneumococcal carriage among Kenyan children
Tekijä: Morpeth, SC, et al.
Julkaistu: (2018)

Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children
Tekijä: Susanna Esposito, et al.
Julkaistu: (2015-01-01)

Hypotonic hyporesponsive episode and the 13-valent pneumococcal vaccine
Tekijä: Lampros Fotis, et al.
Julkaistu: (2014-08-01)

INTERNATIONAL EXPERIENCE WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
Tekijä: David G. McIntosh
Julkaistu: (2009-04-01)

INTERNATIONAL EXPERIENCE WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
Tekijä: David G. McIntosh
Julkaistu: (2009-04-01)

The Burden of Pneumococcal Disease in the Canadian Population Before Routine Use of the Seven-Valent Pneumococcal Conjugate Vaccine
Tekijä: Adrienne Morrow, et al.
Julkaistu: (2007-01-01)

Invasive pneumococcal pneumonia caused by 13-valent pneumococcal conjugate vaccine types in children with different schedules
Tekijä: Hong-Yi Lee, et al.
Julkaistu: (2018-04-01)

Periodic cycles of pneumococcal serotypes carried by children before and after 7-valent pneumococcal conjugate vaccine.
Tekijä: Ana Cristina Paulo, et al.
Julkaistu: (2017-01-01)